These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23867812)

  • 1. Medical product safety surveillance: how many databases to use?
    Maro JC; Brown JS; Kulldorff M
    Epidemiology; 2013 Sep; 24(5):692-9. PubMed ID: 23867812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity.
    Maro JC; Brown JS; Dal Pan GJ; Kulldorff M
    Pharmacoepidemiol Drug Saf; 2014 Aug; 23(8):839-48. PubMed ID: 24700557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of exposure accrual on sequential postmarket evaluations: a simulation study.
    Maro JC; Brown JS
    Pharmacoepidemiol Drug Saf; 2011 Nov; 20(11):1184-91. PubMed ID: 22020903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 5. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Food and Drug Administration's Post-Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise.
    Nguyen M; Ball R; Midthun K; Lieu TA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():291-7. PubMed ID: 22262619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
    Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.
    Rassen JA; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():41-9. PubMed ID: 22262592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing data mining methods on the VAERS database.
    Banks D; Woo EJ; Burwen DR; Perucci P; Braun MM; Ball R
    Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):601-9. PubMed ID: 15954077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active surveillance of postmarket medical product safety in the Federal Partners' Collaboration.
    Robb MA; Racoosin JA; Worrall C; Chapman S; Coster T; Cunningham FE
    Med Care; 2012 Nov; 50(11):948-53. PubMed ID: 23047784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous sequential boundaries for vaccine safety surveillance.
    Li R; Stewart B; Weintraub E; McNeil MM
    Stat Med; 2014 Aug; 33(19):3387-97. PubMed ID: 24691986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Vaccine Safety Datalink: a model for monitoring immunization safety.
    Baggs J; Gee J; Lewis E; Fowler G; Benson P; Lieu T; Naleway A; Klein NP; Baxter R; Belongia E; Glanz J; Hambidge SJ; Jacobsen SJ; Jackson L; Nordin J; Weintraub E
    Pediatrics; 2011 May; 127 Suppl 1():S45-53. PubMed ID: 21502240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccinovigilance in Europe--need for timeliness, standardization and resources.
    Lankinen KS; Pastila S; Kilpi T; Nohynek H; Mäkelä PH; Olin P
    Bull World Health Organ; 2004 Nov; 82(11):828-35. PubMed ID: 15640918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simulation study comparing exposure matching with regression adjustment in an observational safety setting with group sequential monitoring.
    Stratton KG; Cook AJ; Jackson LA; Nelson JC
    Stat Med; 2015 Mar; 34(7):1117-33. PubMed ID: 25510526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
    Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
    [No Abstract]   [Full Text] [Related]  

  • 20. Early adverse drug event signal detection within population-based health networks using sequential methods: key methodologic considerations.
    Brown JS; Kulldorff M; Petronis KR; Reynolds R; Chan KA; Davis RL; Graham D; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2009 Mar; 18(3):226-34. PubMed ID: 19148879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.